Librela, also referred to as the bedinvetmab injection, has been used on pups suffering from osteoarthritis since it was introduced and approved by the US Food and Drug Administration (FDA) in May 2023.
‘The adverse events identified and analyzed include: ataxia, seizures, other neurologic signs, including but not limited to, paresis, recumbency, urinary incontinence; polyuria, and polydipsia,’ stated the FDA in the letter on Monday.
Veterinarians who see dogs display symptoms after being treated with Librela are urged to report it to the drug sponsor, Zoetis, which is required to inform the FDA.
The FDA stated that it reviewed available studies on the Librela and determined it to be safe for controlling pain from osteoarthritis, before granting the approval.
Popular medication for dogs is sickening and killing them A medication meant to help dogs with pain has been found to kill them.
